www.hiv-drinteractions.org

UNIVERSITY OF LIVERPOOL

Anticoagulant & Antiplatlet Treament Selector

Charts reviewed January 2017. Full information available at www.hiv-druginteractions.org

For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution.

		ATV/r	DRV/r	LPV/r	EFV	ETV	NVP	RPV	MVC	DTG	RAL	ABC	FTC	3TC	TDF	ZDV	E/C/F/TAF	E/C/F/TDF
Anticoagulants	Acenocoumarol	↓	↓	↓	↓	↑	↓	↔	↔	↔	↔	↔	↔	↔	↔	↔	↓	↓
	Apixaban	↑	↑	↑	↓	↓	↓	↔	↔	↔	↔	↔	↔	↔	↔	↔	↑	↑
	Dabigatran	↑	↑	↑?	↔	↔	↔	↑?	↔	↔	↔	↔	↔	↔	↔	↔	↑	↑
	Dalteparin	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
	Edoxaban	↑	↑	↑	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↑	↑
	Enoxaparin	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
	Fondaparinux	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
	Heparin	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
	Phenprocoumon	↓↑[a]	↓↑	↓↑	↓	↓↑	↓	↔	↔	↔	↔	↔	↔	↔	↔	↔	↓↑	↓↑
	Rivaroxaban	↑	↑	↑	↓	↓	↓	↔	↔	↔	↔	↔	↔	↔	↔	↔	↑	↑
	Warfarin	↓↑[a]	↓	↓	↓↑	↑	↓↑	↔	↔	↔	↔	↔	↔	↔	↔	↔	↓	↓
Antiplatelet Agents	Aspirin	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	b	↔	↔	b
	Clopidogrel	↓[c]	↓[c]	↓[c]	↑[d]	↓[c]	↑[d]	↔	↔	↔	↔	↔	↔	↔	↔	↔	↓[c]	↓[c]
	Dipyridamole	↓[e]	↓	↓	↓	↓	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
	Prasugrel	↓[f]	↓[f]	↓[f]	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↓[f]	↓[f]
	Ticagrelor	↑	↑	↑	↓	↓	↓	↔	↔	↔	↔	↔	↔	↔	↔	↔	↑	↑

Colour Legend

- No clinically significant interaction expected.
- These drugs should not be coadministered.
- Potential interaction which may require a dosage adjustment or close monitoring.
- Potential interaction predicted to be of weak intensity (<2 fold ↑AUC or <50% ↓AUC). No *a priori* dosage adjustment is recommended.

Text Legend

↑ Potential increased exposure of the anticoagulant/antiplatelet agent
↓ Potential decreased exposure of the anticoagulant/antiplatelet agent
↔ No significant effect

a Unboosted ATV predicted to increase the anticoagulant. Monitor INR and adjust the anticoagulant dosage accordingly.
b Potential risk of nephrotoxicity. Monitoring of renal function recommended.
c Decreased conversion to active metabolite leading to non-responsiveness to clopidogrel. An alternative to clopidogrel should be considered.
d Increase in amount of active metabolite via induction of CYP3A4 and CYP2B6.
e Unboosted ATV predicted to increase dipyridamole exposure due to UGT1A1 inhibition.
f Reduced active metabolite but without a significant reduction in prasugrel activity.

Abbreviations: ATV atazanavir, ABC abacavir, DRV darunavir, FTC emtricitabine, LPV lopinavir, 3TC lamivudine, /r ritonavir, TDF tenofovir disoproxil fumarate, EFV efavirenz, ETV etravirine, ZDV zidovudine, NVP nevirapine, E/C/F/ Elvitegravir/Cobicistat/FTC, RPV rilpivirine, MVC maraviroc, TAF tenofovir alafenamide, DTG dolutegravir, RAL raltegravir

© Liverpool Drug Interactions Group, University of Liverpool, Pharmacology Research Labs, 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF.
We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.